Mammalian Cell Cultures for Biologics Manufacturing

  • Anne KantardjieffEmail author
  • Weichang Zhou
Part of the Advances in Biochemical Engineering/Biotechnology book series (ABE, volume 139)


Biopharmaceuticals represent a growing sector of the pharmaceutical industry, and are used for a wide range of indications, including oncology and rheumatology. Cultured mammalian cells have become the predominant expression system for their production, partly due to their ability to complete the posttranslational modifications required for drug safety and efficacy. Over the past decade, the productivity of mammalian cell culture production processes has growth dramatically through improvements in both volumetric and specific productivities. This article presents an overview of the biologics market, including analysis of sales and approvals; as well as a review of industrial production cell lines and cell culture operations.

Graphical Abstract


Biopharmaceuticals Cell culture operations Mammalian cell culture Production cell lines 


  1. 1.
    Aggarwal S (Rob) (2012) What’s fueling the biotech engine—2011 to 2012. Nat Biotechnol 30(12):1191–1197Google Scholar
  2. 2.
    Aggarwal S (Rob) (2007) What’s fueling the biotech engine? Nat Biotechnol 25(10):1097–1104Google Scholar
  3. 3.
    De Jesus M, Wurm F (2011) Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. Eur J Pharm Biopharm 78:184–188CrossRefGoogle Scholar
  4. 4.
    Kim JY, Kim Y-G, Lee GM (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microb Biotechnol 93:917–930Google Scholar
  5. 5.
    Kling J (2012) Fresh from the biotech pipeline—2011. Nat Biotechnol 30(2):128–131CrossRefGoogle Scholar
  6. 6.
    La Merie Business Intelligence (2013) Blockbuster Biologics 2012. R&D Pipeline News, May 7 2013, Special Edition 1Google Scholar
  7. 7.
    Osborne R (2013) Fresh from the biotech pipeline—2012. Nat Biotechnol 31(2):100–103CrossRefGoogle Scholar
  8. 8.
    Walsch G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28(9):917–924CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Upstream DevelopmentAlexion PharmaceuticalsCheshireUSA
  2. 2.Biologics process DevelopmentWuXi AppTec Co.ShanghaiChina

Personalised recommendations